T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy

Cancer Discov. 2014 May;4(5):522-6. doi: 10.1158/2159-8290.CD-13-0985.

Abstract

Cancer immunotherapy has great promise, but is limited by diverse mechanisms used by tumors to prevent sustained antitumor immune responses. Tumors disrupt antigen presentation, T/NK-cell activation, and T/NK-cell homing through soluble and cell-surface mediators, the vasculature, and immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells. However, many molecular mechanisms preventing the efficacy of antitumor immunity have been identified and can be disrupted by combination immunotherapy. Here, we examine immunosuppressive mechanisms exploited by tumors and provide insights into the therapies under development to overcome them, focusing on lymphocyte traffic.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Immunotherapy / methods*
  • Killer Cells, Natural / immunology*
  • Lymphocyte Activation
  • Neoplasms / immunology
  • Neoplasms / therapy*
  • T-Lymphocytes / immunology*
  • Tumor Microenvironment